AKT1 and breast carcinoma: Our results suggest that in vivo, but not ex vivo, both breast cancer models become dependent upon co-activation of FGFR and ErbB receptors for PI3K/Akt/mTOR pathway activity, demonstrating the importance of the tumor environment in influencing receptor activity and response to targeted inhibitors.